Loading
A phase 2/3 trial of Cytarabine in acute myeloid leukaemia, run by Moleculin Biotech, Inc., now recruiting.
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML is a phase 2/3 interventional study registered as NCT06788756 by Moleculin Biotech, Inc., with 312 participants planned, started 2025-03-12 and due to reach its primary completion in 2029-08. Interventions recorded: Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.. Conditions listed: Acute Myeloid Leukaemia (AML). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cytarabine, Acute myeloid leukaemia.
Shares Cytarabine, Acute myeloid leukaemia, Cytotoxic chemotherapy.
Shares Cytarabine, Acute myeloid leukaemia, Cytotoxic chemotherapy.
Shares Cytarabine, Acute myeloid leukaemia.
Shares Cytarabine, Acute myeloid leukaemia, Cytotoxic chemotherapy.
Shares Cytarabine, Acute myeloid leukaemia.
Shares Cytarabine, Acute myeloid leukaemia.
Shares Cytarabine, Acute myeloid leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/